First clinical experience using a novel 8-spline ultra high-resolution mapping catheter to guide atrial fibrillation ablation

Abstract

Abstract Background Multielectrode mapping catheters improve the detection of scarred and fibrotic tissue in patients with atrial fibrillation (AF) Recently, a novel multispline mapping catheter with 48 closely spaced microelectrodes has been introduced enabling fast high-resolution electroanatomical mapping. Objective This study sought to report our initial clinical experience with the novel Octaray catheter in patients with AF undergoing index ablation and to compare its impact on mapping and ablation with the 5-spline Pentaray catheter. Methods The study included consecutive patients who underwent index AF ablation using a multipolar mapping catheter and very high-power-short-duration guided ablation (Q4U-AF workflow; QDot; Qmode+; Biosense Webster) in conjunction with a visualized sheath (Vizigo; Biosense Webster). Arrhythmia recurrence was defined as any atrial fibrillation (AF)/ atrial tachycardia (AT) episode lasting > 30 s after a blanking period of 3 months. Results A total number of 183 patients undergoing AF ablation using the Octaray and QDot catheter were compared to a group of 166 matched patients who underwent ablation using Pentary and QDot. Utilization of the Octaray catheter resulted in an increased identification of areas with bipolar low-voltage representing fibrosis/scar or atrial cardiomyopathy (mean amount of left atrial bipolar low-voltage: Octaray 31% vs. Pentaray 18%; p= 0.03) and a higher rate of first-pass isolation (FPI) for the left-sided pulmonary veins (Octaray: FPI rate 73% vs. FPI rate 64% for Pentaray). A significantly higher number of mapping points was acquired using the novel 8-spline mapping catheter (right atrium: Octaray 1936 points vs. Pentaray 903 points; p < 0.001 left atrium: Octaray 5337 points vs. Pentaray 2385 points; p < 0.001). Procedural parameter, radiation time/dosage and acute procedural success were comparable between the two groups. During a mean follow-up of 12 months, the overall procedural success was 86 in the Octaray group vs. 84% in the control group (p=0.9). Conclusion The utilization of the novel Octaray mapping catheter resulted in an improved detection of atrial fibrosis and scar as well as a higher rate of first-pass pulmonary vein isolation. Figure: Institutional Q4U-AF-workflow using a multipolar mapping catheter, the QDot ablation catheter and a visualized sheath. High resolution mapping using the Octaray (A+B) and PentaRay catheter (C+D).